Arrakis Therapeutics vs Moderna

Arrakis Therapeutics vs Moderna, compared side by side on 17 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: Arrakis Therapeutics is on 46/100 and Moderna on 77/100.

Arrakis Therapeutics logo
Arrakis TherapeuticsArrakis Therapeutics is a biopharmaceutical company developing oral medicines that target RNA to treat a range of diseases. The company is based in Waltham, Mas
Try Arrakis Therapeutics
Moderna logo
ModernaModerna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.
Try Moderna

Where each one leads

Arrakis Therapeutics

Leads on none of the measures we hold for both companies.

Moderna

  • our overall score: 77/100 against 46/100
  • agent readiness: 49/100 against 37/100
  • domain rating: 79/100 against 29/100
  • headcount: 6,297 against 52
  • LinkedIn following: 780,086 against 12,956

At a glance

MeasureArrakis TherapeuticsModerna
What it isArrakis Therapeutics is a biopharmaceutical company developing oral medicines that target RNA to treat a range of diseases. The company is based in Waltham, MasModerna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.
CategoryBiotech, Drug Discovery, RNA Therapeutics, Small Molecule DrugsBiotechnology, mRNA Technology, Vaccines, Pharmaceuticals
Sells toBusiness modelB2BB2B
OfferingSoftwareServices
Founded20142010
HeadquartersWaltham, United StatesCambridge, United States
StatusActiveActive

Size, funding and growth

MeasureArrakis TherapeuticsModerna
Employees526,297
Open rolesNot published100
Total fundingNot published$4.5B
Latest roundNot publishedFunding Round
LinkedIn followers12,956780,086

StartupHub scores

Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.

MeasureArrakis TherapeuticsModerna
StartupHub scoreOur 0-100 rating46/10077/100
Traction17/10060/100
TeamNot published70/100
CommunityNot published13/100
Search visibility34/10046/100
Quality68/10090/100
Agent readinessHow well an AI agent can read and act on the siteF (37/100)D (49/100)
Domain ratingLink authority, 0-10029/10079/100

Technology

Detected on each public site, so it reflects the marketing stack as well as the product.

MeasureArrakis TherapeuticsModerna
HostingNot detectedAWS
CDNCloudflareCloudFront
CMSWordPressNot detected
FrameworksJqueryNext.js
AnalyticsGoogle Analytics 4Not detected

What users say

MeasureArrakis TherapeuticsModerna
Community ratingVisitor votes on StartupHubNot published2.0/5 from 1 vote
Reddit sentimentThreads we track2 positive, 2 negative across 4 threadsNot published
Arrakis Therapeutics
Pharmaunternehmen - Roche schliesst Lizenzvereinbarung mit Arrakis Therapeutics, Der Pharmakonzern Roche hat sich auf eine Lizenzvereinbarung mit dem US-Biotechunternehmen Arrakis Therapeutics geeinigt..
r/chpresseschau

Arrakis Therapeutics vs Moderna: common questions

Which is better, Arrakis Therapeutics or Moderna?

On our 0-100 score Moderna rates higher (77/100 against 46/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 17 data points above: read the rows that match what you are buying for.

How do Arrakis Therapeutics and Moderna compare on the numbers?

Moderna leads on our overall score (77/100 against 46/100), agent readiness (49/100 against 37/100), domain rating (79/100 against 29/100), headcount (6,297 against 52), LinkedIn following (780,086 against 12,956).

What do real users say about Arrakis Therapeutics and Moderna?

Arrakis Therapeutics: 2 positive and 2 negative mentions across 4 Reddit threads we track, mostly in r/chpresseschau.

Read the full Arrakis Therapeutics review and pricing or the Moderna review and pricing. You can also browse other Arrakis Therapeutics alternatives we track.